More than 90% of patients with relapsed or refractory multiple myeloma who received the two highest doses of REGN5459 responded to treatment with the investigational bispecific antibody, results of a phase 1/phase 2 study showed.
REGN5459 (Regeneron Pharmaceuticals) — which targets the B-cell maturation antigen (BCMA) and CD3 — exhibited a manageable safety, with low incidence of severe cytokine release syndrome or neurotoxicity, according to the findings, presented at American Association for Cancer Research Annual Meeting.
The novel therapy’s use of a low-affinity binding
